ABAX 55.02 Abaxis Inc $ABAX Hit a 52 week high of
Post# of 44
ABAX Recent Posts: http://investorshangout.com/Abaxis-ABAX-53195/
ABAX Abaxis Inc Recent Headline News
Strength Seen in Cerus (CERS): Stock Gains 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 8:25AM CST
Cerus (CERS) was a big mover last session, with shares rising nearly 6% on the day.
CERS: 4.43 (+0.02), ABAX: 55.23 (+0.43), GWPH: 76.09 (+0.46), OSUR: 8.89 (+0.12)
Abaxis, Inc. to Present at the Canaccord Genuity Medical Technology & Diagnostic Forum
PR Newswire - Fri Nov 14, 7:00AM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood instrumentation and consumables to the medical, research and veterinary markets, announced today that Don Wood, Chief Operating Officer, will present at the Canaccord Genuity 2014 Medical Technology & Diagnostics Forum on Thursday, November 20, 2014 at 8:00 a.m. ET. The conference will be held at The Westin Grand Central Hotel in New York City.
ABAX: 55.23 (+0.43)
Allscripts Healthcare and CHI Sign Hosting Solution Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:40PM CST
By utilizing Allscripts Healthcare Solutions, Inc. (MDRX) Hosting Solution, Catholic Health Initiatives expects improved system availability, reduced IT infrastructure expenditures as well as enhanced end user performance.
GWPH: 76.09 (+0.46), ABAX: 55.23 (+0.43), MDRX: 12.51 (+0.07), MRGE: 3.28 (+0.04)
3 Stocks Going Ex-Dividend Tomorrow: ERH, PHT, ABAX
at The Street - Wed Nov 12, 9:52AM CST
ERH PHT ABAX are going ex-dividend tomorrow, Thursday, November 13, 2014
PHT: 17.58 (-0.04), ERH: 13.34 (+0.14), ABAX: 55.23 (+0.43)
Meridian Bioscience (VIVO) Misses Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:20AM CST
Meridian Bioscience Inc. (VIVO) reported fourth-quarter fiscal 2014 earnings of 20 cents per share, which missed the Zacks Consensus Estimate by a couple of cents
BSX: 13.38 (+0.02), VIVO: 16.20 (+0.01), ABAX: 55.23 (+0.43), OSUR: 8.89 (+0.12)
INSYS Therapeutics (INSY) in Focus: Stock Rises 12% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 7:44AM CST
INSYS Therapeutics, Inc. (INSY) was a big mover last session, as the company saw its shares surge 12%
ICUI: 86.13 (+0.42), INSY: 38.77 (+0.20), ABAX: 55.23 (+0.43), GWPH: 76.09 (+0.46)
Omeros (OMER) Catches Eye: Stock Jumps 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 7:30AM CST
Omeros Corporation (OMER) was a big mover last session, as the company saw its shares rise almost 9% on the day.
ABAX: 55.23 (+0.43), GWPH: 76.09 (+0.46), OSUR: 8.89 (+0.12), OMER: 19.30 (+0.32)
Abaxis, Inc. to Present at the Stifel 2014 Healthcare Conference
PR Newswire - Wed Nov 12, 7:00AM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood instrumentation and consumables to the medical, research and veterinary markets, announced today that Don Wood, Chief Operating Officer, will present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 9:45 a.m. ET. The conference will be held at the New York Palace Hotel in New York City.
ABAX: 55.23 (+0.43)
Omnicell Reports Mixed Q3, Positive on Surgichem Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 2:00PM CST
On Nov 6, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.38 (+0.02), ICUI: 86.13 (+0.42), ABAX: 55.23 (+0.43), OMCL: 32.59 (+0.33)
Boston Scientific Shows Strength on Core Market Stabilization - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 1:50PM CST
On Nov 7, 2014, we issued an updated research report on leading medical devices company Boston Scientific Corporation (BSX).
BSX: 13.38 (+0.02), ICUI: 86.13 (+0.42), BCR: 164.40 (+0.36), ABAX: 55.23 (+0.43)
Ex-Dividend Reminder: Abaxis, Chemed and AmerisourceBergen
DividendChannel.com - Tue Nov 11, 9:50AM CST
Looking at the universe of stocks we cover at Dividend Channel, on 11/13/14, Abaxis, Inc. , Chemed Corp , and AmerisourceBergen Corp.
ABAX: 55.23 (+0.43)
Eagle Pharmaceuticals (EGRX) Jumps: Stock Gains 8.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:46AM CST
Eagle Pharmaceuticals (EGRX) was a big mover last session, with shares rising over 8% on the day.
ICUI: 86.13 (+0.42), ABAX: 55.23 (+0.43), GWPH: 76.09 (+0.46), EGRX: 12.70 (+0.04)
Walgreens Hits the Rock with Court's Ruling on CFO Lawsuit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 2:30PM CST
The controversy surrounding an inflated fiscal 2016 earnings forecast continues for leading drugstore chain Walgreen Co. (WAG).
BSX: 13.38 (+0.02), ICUI: 86.13 (+0.42), ABAX: 55.23 (+0.43), WAG: 66.80 (-0.13)
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 211.86 (+13.21), EBS: 24.18 (-0.04), ABAX: 55.23 (+0.43), ABBV: 64.95 (+0.95)
Meridian Bioscience (VIVO) Falls: Stock Goes Down 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:55AM CST
Meridian Bioscience saw a big move last session, as the company’s shares fell by nearly 6% which continued the recent downtrend
VIVO: 16.20 (+0.01), ABAX: 55.23 (+0.43), GWPH: 76.09 (+0.46), OSUR: 8.89 (+0.12)
BioScrip (BIOS) Q3 Loss Wider than Expected, Revenues Top - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:10PM CST
BioScrip, Inc. (BIOS) recently declared its third-quarter 2014 results.
BSX: 13.38 (+0.02), ICUI: 86.13 (+0.42), ABAX: 55.23 (+0.43), BIOS: 5.77 (-0.14)
Allscripts Healthcare Q3 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 12:30PM CST
Allscripts Healthcare Solutions, Inc. (MDRX) posted adjusted earnings of 2 cents per share in the third quarter of 2014 which missed the Zacks Consensus Estimate by 3 cents.
GWPH: 76.09 (+0.46), ABAX: 55.23 (+0.43), MDRX: 12.51 (+0.07), MRGE: 3.28 (+0.04)
Omnicell Earnings Hit by High Tax, User Addition Aids Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:27AM CST
On Nov 7, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.38 (+0.02), ICUI: 86.13 (+0.42), ABAX: 55.23 (+0.43), OMCL: 32.59 (+0.33)
SurModics Beats on Q4 Earnings, Issues Fiscal 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:10AM CST
SurModics, Inc.???s fourth-quarter fiscal 2014 adjusted earnings of 26 cents per share beat the Zacks Consensus Estimate by a penny.
AGN: 211.86 (+13.21), SRDX: 21.74 (+0.28), ABAX: 55.23 (+0.43), ABBV: 64.95 (+0.95)
Wright Medical Posts Wider Q3 Loss; Lowers '14 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:50AM CST
Following the earnings release, shares of Wright Medical Group Inc. (WMGI) dropped nearly 5.7% to close at $28.44 yesterday.
BSX: 13.38 (+0.02), WMGI: 28.29 (+0.21), GWPH: 76.09 (+0.46), ABAX: 55.23 (+0.43)